Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

DURECT Corporation (DRRX)

1.86   -0.23 (-11%) 02-25 16:00
Open: 2.05 Pre. Close: 2.09
High: 2.13 Low: 1.86
Volume: 1,232,598 Market Cap: 358M
Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and Drug Delivery Programs.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.132 - 2.144 2.144 - 2.153
Low: 1.835 - 1.848 1.848 - 1.859
Close: 1.84 - 1.86 1.86 - 1.877

Technical analysis

as of: 2020-02-25 4:28:53 PM
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 2.50     One year: 2.91
Support: Support1: 1.57    Support2: 1.31
Resistance: Resistance1: 2.14    Resistance2: 2.49
Pivot: 1.93
Moving Average: MA(5): 2.05     MA(20): 1.94
MA(100): 2.11     MA(250): 1.42
MACD: MACD(12,26): -0.05     Signal(9): -0.09
Stochastic oscillator: %K(14,3): 69.12     %D(3): 77.78
RSI: RSI(14): 42.77
52-week: High: 3.95  Low: 0.50  Change(%): 129.6
Average Vol(K): 3-Month: 163440  10-Days: 114482

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
DRRX has closed above bottom band by 41.2%. Bollinger Bands are 5.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

DURECT Corporation Announces Top-Line Results from Phase 2a Clinical Trial in Patients with Psoriasis
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the results from its Phase 2a clinical trial of DUR-928 in patients with mild to moderate…

The Daily Biotech Pulse: Qiagen Opts To Stay Solo Following Strategic Review, Spectrum Slumps On Negative Data, Microbot Medical To Offer Shares
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Dec. 24.) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) Cassava Sciences Inc (NASDAQ: SAVA ) ChemoCentryx Inc (NASDAQ: CCXI ) Clearside Biomedical Inc (NASDAQ: CLSD ) DURECT Corporation (NASDAQ: DRRX ) Eiger Biopharmaceuticals Inc (NASDAQ: EIGR ) Esperion Therapeutics Inc (NASDAQ: ESPR ) Exagen Inc (NASDAQ: XGN ) Forty Seven Inc (NASDAQ: FTSV ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Harpoon Therapeutics Inc (NASDAQ: HARP ) Horizon Therapeutics PLC (NASDAQ: HZNP ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Karyopharm Therapeutics Inc (NASDAQ: KPTI ) Kodiak Sciences Inc (NASDAQ: KOD ) (JPMorgan initiated coverage with an Outperform rating) Microbot Medical Inc (NASDAQ: MBOT ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Momenta Pharmaceuticals, Inc.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Global Market
Sector:  Healthcare
Industry:  Drug Manufacturers - Specialty Generic
Shares Out. (M) 192.36
Shares Float (M) 167.00
% Held by Insiders 3.36
% Held by Institutions 45.13
Shares Short (K) 4120
Shares Short P. Month (K)

Stock Financials

EPS -0.139
Book Value (p.s.) 0.110
PEG Ratio -0.95
Profit Margin -105.07
Operating Margin -100.34
Return on Assets (ttm) -19.5
Return on Equity (ttm) -98.3
Qtrly Rev. Growth 33.9
Gross Profit (p.s.) -0.058
Sales Per Share
EBITDA (p.s.) -0.116
Qtrly Earnings Growth
Operating Cash Flow (M) 1.02
Levered Free Cash Flow (M) 6.70

Stock Valuations

P/E -13.38
P/E Growth Ratio -0.11
P/BV 16.91
P/S 14.30
P/CF 350.77

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.